Related Experiment Video
Updated: Nov 12, 2025
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.1K
Very-Low-Dose Levodopa Therapy for Pediatric Neurological Disorders: A Preliminary Questionnaire in Japan
Kyoko Hoshino1,2,3, Masaharu Hayashi1,2,4, Asayo Ishizaki2,5
1Segawa Memorial Neurological Clinic for Children, Tokyo, Japan.
Frontiers in Pediatrics
|March 22, 2021
Summary
Very-low-dose levodopa therapy (VLDT) shows promise for treating pediatric neurological disorders, effectively managing behavioral and motor symptoms with a low incidence of adverse events. This approach is considered safer than dopamine antagonists, which have significant side effects.
Area of Science:
- Pediatric Neurology
- Neuropharmacology
- Dopamine Receptor Supersensitivity
Background:
- Post-synaptic dopamine receptor supersensitivity (DARSS) is a researched condition.
- Very-low-dose levodopa therapy (VLDT), 0.5-1 mg/kg/day, has been investigated for potential therapeutic use.
- Japanese research suggests VLDT may treat pediatric neurological disorders.
Purpose of the Study:
- To collect real-world data on the use of VLDT for treating DARSS in pediatric patients.
- To assess the efficacy and safety of VLDT in managing various pediatric neurological conditions.
Main Methods:
- An online, two-step survey (screening test and questionnaire) was conducted in 2014.
- The survey was distributed via the VLDT Research Group home page.
- 1,165 pediatric neurologists in Japan were invited to participate.
Main Results:
- 25 neurologists reported prescribing VLDT for conditions including autism spectrum disorder, tics, speech delay, Rett syndrome, ADHD, intellectual disability, and sleep problems.
- VLDT demonstrated effectiveness in treating behavioral problems (22 respondents) and motor symptoms (20 respondents).
- Low incidence of adverse events was reported; VLDT was chosen for its safety and potential action in DARSS.
Conclusions:
- VLDT appears to be a safe and effective treatment for behavioral and motor symptoms in pediatric neurological disorders.
- VLDT offers a safer alternative compared to dopamine antagonists, which are associated with adverse effects like somnolence and obesity.
- Further research with broader participation is recommended to validate these findings.
Related Concept Videos
01:24Parkinson's Disease: Treatment
708
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
708
01:29Drug Dosing: Infants and Children
87
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
87
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
80
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
80
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
76
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
76
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
114
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
114
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
85
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
85